This study (published by Munkh- Erdene Lusvan, M.; Debellut. F.; Clark,A.; Demberelsuren, S.; Otgonbayar, D.; Batjargal, T.; Purevsuren, S.; Groman, D.; Tate, J.; Pecenka, C. in Vaccine, Volume 37, Issue 6, 4 February 2019), examines the use of the two-dose vaccine ROTARIX®, and three-dose vaccines ROTAVAC® and RotaTeq® compared to no vaccination from the government and the societal perspective. The authors find that rotavirus vaccination in Mongolia could avert more than 95,000 rotavirus cases and 271 deaths, over 10 years. Averted visits and hospitalizations represent US$2.4 million in health care costs saved by the government. The vaccination program cost ranges from $6 to $11 million depending on vaccine choice. From the governmental perspective, ICER ranged from $412 to $1050 and from $77 to $715 when considering the societal perspective. Sensitivity analysis highlights vaccine price as the main driver of uncertainty. They conclude that Introduction of rotavirus vaccin